Biology & Life Sciences

Synthetic tumour microenvironment (TME) models could help bridge the gap between simplified in-vitro assays and heterogeneous patient tumours. This project will explore what a useful, practical synthetic TME should reproduce for cancer-therapeutics discovery.

Initial questions:

• Which components are essential for a minimum viable model: tumour cells, stromal cells, immune cells, extracellular matrix, perfusion, gradients, or hypoxia?
• Which therapeutic questions benefit most from synthetic TME models: immune-cell engagement, resistance mechanisms, combination therapy, toxicity, or patient stratification?
• Which readouts should define translational value: tumour-cell killing, immune-state changes, spatial organisation, biomarker response, or concordance with clinical outcomes?
• How should models be benchmarked against patient samples, organoids, animal models, and clinical data?

The goal is not to reproduce every aspect of a tumour. It is to identify the smallest model that is fit for a defined discovery decision.

TL;DR

This project aims to utilise a genome-wide CRISPR-Cas9 knockout screen to identify novel senolytic drug targets whilst providing new mechanistic insights into how senescent cells function and survive.

Background information

Cellular senescence is a phenomenon in which damaged or stressed cells irreversibly exit the cell cycle and adopt a pro-inflammatory phenotype, disrupting tissue homeostasis and causing cytotoxic effects on neighbouring cells.

Senescent cells accumulate with age in humans and are associated with numerous diseases, including osteoarthritis, cardiovascular disease, cancer, and neurodegeneration. In animal models, the targeted removal of senescent cells has been shown to improve health and extend lifespan. Consequently, there is substantial therapeutic interest in developing senolytics - drugs that selectively eliminate senescent cells¹.

As global populations continue to age and the incidence of age-related diseases rises, the need for effective interventions grows accordingly. As the removal of senescent cells has the potential to address a broad spectrum of age-associated conditions, the global market for senolytics is positioned to be a multibillion-dollar opportunity across multiple therapeutic areas. 

Approach

Synthetic lethality is the biological phenomenon whereby inactivation of either gene A or B is tolerable, yet the loss of both is lethal². Using this approach for target discovery has seen great success in the cancer field, for example the development of PARP inhibitors for treating BRCA-deficient cancers³. Whilst early attempts relied on RNA interference methods, the advent of CRISPR-based gene editing has made full genome screening more tangible/scalable to the point where numerous big pharma companies have synthetic lethality cancer drug discovery programmes.

Senescence research has established that numerous proteins show differential abundance in proliferating versus senescent cells. For example SIRT1, HMGB2⁴, MCM⁵ proteins, Lamin B1⁶ and several others are present at extremely low levels / absent in senescent cells. These proteins therefore represent attractive “bait” genes for synthetic lethality experiments.

I now propose that synthetic lethality should be applied to longevity research to discover new drug targets to selectively kill senescent cells.

Experimental Plan

Months 1-2: Create a stable knock-out cell line for the “bait” gene of interest.

Months 3-4: Perform a genome-wide CRISPR-Cas9 knockout screen in wild type vs knock-out cells.

Months 5-6: Next Generation Sequencing and MAGeCK analysis to determine which genes are essential for the survival of knock-out cells.

Months: 7-8: Senolytic validation - determine which hits are essential for senescent cell survival by knocking-out the genes of the top screen hits in proliferating vs senescent cells and perform cell viability assays.

Project Outputs and Future directions

Upon completing these experiments, we hope to identify a number of genes that are essential for the survival of senescent cells, with the most compelling hits serving as novel senolytic targets for future drug-discovery campaigns.

In addition to their translational potential, these genes will provide a foundation for further basic research aimed at elucidating the mechanisms that render them critical for senescent-cell viability.

References:

1. <u>Senescence as a therapeutic target in cancer and age-related diseases</u>
2. <u>Synthetic lethality in cancer drug discovery: challenges and opportunities</u>
3. <u>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</u>
4. <u>HMGB2 Loss upon Senescence Entry Disrupts Genomic Organization and Induces CTCF Clustering across Cell Types</u>
5. <u>Changes in MCM2-7 proteins at senescence</u>
6. <u>Lamin B1 loss is a senescence-associated biomarker</u>

Commensal gut bacteria can be genetically engineered to detect molecular signatures of inflammation (such as nitric oxide or specific metabolites) and respond by producing and releasing therapeutic compounds locally — effectively turning a patient's own microbiome into a self-regulating drug factory that only activates where and when disease is present.

The Elephant in the SCIF

Here's something that gets discussed in DMs but rarely in public: a non-trivial fraction of the people doing the most important work in cybersecurity, biosecurity, AI safety, and adjacent fields use prescription amphetamines. Some daily, as prescribed for ADHD. Some intermittently—Vyvanse or Adderall once a week, or during crunch periods when the alternative is shipping a vulnerability assessment late or missing a critical window in a fast-moving threat landscape.

This isn't controversial to anyone who's actually in these communities. What's controversial is saying it out loud, because the conversation immediately collapses into one of two useless attractors: "stimulants are fine, they're prescribed by doctors" or "you're frying your dopamine system." Neither engages with the actual evidence, which is—as our companion research brief documents in detail—genuinely, uncomfortably uncertain in exactly the range that matters.

We think this uncertainty is worth engaging with directly, because the stakes on both sides are real. Underperformance during critical windows in cybersecurity incident response or pandemic preparedness has concrete, measurable costs. And so does iatrogenic dopaminergic damage to the people we most need thinking clearly in five and ten years.

Important framing note before we get into it: The overwhelming majority of neurotoxicity data comes from methamphetamine (METH) and MDMA, not d-amphetamine or mixed amphetamine salts. These are pharmacologically related but not identical. Methylphenidate has a substantially different mechanism (reuptake inhibitor without significant vesicular release) and generally shows a more favorable safety profile. Conflating the three is a common error in both directions—both in dismissing risk and in catastrophizing it. We'll be precise about which compound the evidence actually involves throughout.

Part I: What the Evidence Actually Shows

Dose, Spacing, and Recovery Dynamics

The neurotoxicity of amphetamines is dose-dependent across all species tested. In rodents, high "binge" doses (typically 4×5–10 mg/kg at 2-hour intervals, injected) reliably produce long-lasting striatal dopamine depletion, while repeated lower doses equivalent to the human therapeutic range generally do not produce detectable toxicity (Seiden & Ricaurte, 1987; reviewed in Advokat, 2007).

But dosing pattern matters independently of total dose. Amphetamine administered continuously via osmotic minipumps, or at short intervals (every 2 hours), can produce neurotoxic effects at lower per-dose amounts than widely-spaced dosing (Ricaurte et al., 1984; Sonsalla et al., 1989). This is the core finding that matters for the intermittent-use question: there is a time-dependent capacity for the dopaminergic system to handle oxidative load, and saturating that capacity by eliminating inter-dose recovery windows lowers the damage threshold.

This maps onto the pattern many people have independently converged on: use stimulants once or twice per week, for specific high-priority work blocks, with full recovery days between. The mechanistic logic is sound—but we want to be honest that this is mechanistically plausible extrapolation from preclinical data plus anecdotal convergence, not a validated protocol. No human trial has directly measured dopamine terminal integrity as a function of dosing schedule. The interplay between sensitization (which could lower thresholds over time) and tolerance (which could raise them) creates non-linear dynamics that haven't been adequately modeled.

The recovery-rate framing. Acute amphetamine administration redistributes vesicular dopamine to the cytoplasm, where it undergoes autoxidation to produce a roughly threefold increase in free radicals (Bhatt et al., 2001; Lotharius & O'Malley, 2001). Despite this, protein oxidation doesn't appear until ~1 day later, and cell death not until ~4 days (Lotharius & O'Malley, 2001), suggesting substantial buffering capacity that recovers between exposures. The question is whether daily therapeutic dosing stays within this buffer, or whether chronic exposure gradually depletes antioxidant reserves (particularly glutathione) such that cumulative damage accrues. Weekly dosing with multi-day recovery windows should keep you well within the buffer—but "should" based on mechanism and "does" based on evidence are different things.

The Mechanistic Cascade: How Damage Actually Happens

Understanding the causal sequence matters for knowing where to intervene. Park et al. (2017) dissected this step-by-step in rats:

Energy failure → excitotoxicity → free radical formation → striatal DA depletion.

Specifically: amphetamine redistributes vesicular DA to the cytoplasm via VMAT2 reversal. Cytoplasmic DA auto-oxidizes to produce reactive oxygen species, dopamine quinones, and downstream protein modifications. This is amplified by a feedforward loop: glutamate release from corticostriatal afferents during stimulant exposure → calcium influx → mitochondrial dysfunction → further ROS generation (reviewed in Yamamoto & Raudensky, 2008; Quinton & Yamamoto, 2006).

The ordering matters pharmacologically. Nicotinamide (NAM), an electron transport chain cofactor, blocked AMPH-induced free radical formation, energy failure, and striatal DA decrease. MK-801 (an NMDA antagonist) blocked free radical formation and DA depletion but not energy failure—indicating excitotoxicity occurs after energy failure but before free radical generation in the causal chain (Park et al., 2017). This tells you that energy substrate support is upstream of excitotoxic damage, which is upstream of oxidative damage. Interventions targeting earlier steps protect against more of the cascade.

Circuit Specificity: What Gets Damaged and What Doesn't

The neurotoxicity literature overwhelmingly focuses on the striatum (caudate/putamen), for good mechanistic reasons: this is where dopamine concentration is highest, where the most DA autoxidation occurs, and where the most robust depletion effects are measured. METH toxicity to DA neurons occurs primarily in striatal terminals while relatively sparing other DA-rich areas (Ricaurte et al., 1980; Wagner et al., 1980; Hotchkiss & Gibb, 1980).

The selective vulnerability of striatal DA terminals involves convergence of multiple factors: (1) high dopamine concentration → more substrate for autoxidation to dopamine quinones; (2) high iron content in basal ganglia → Fenton chemistry amplifying ROS; (3) glutamate release from corticostriatal afferents during stimulant exposure → excitotoxic coupling with oxidative stress; (4) hyperthermia as a critical cofactor (METH neurotoxicity is markedly attenuated by preventing temperature elevation—in every animal model tested); (5) mitochondrial complex dysfunction (decreased complex I–II in striatum; decreased complex IV across striatum, nucleus accumbens, and substantia nigra) (MDMA data reviewed in Yamamoto & Raudensky, 2008; Quinton & Yamamoto, 2006).

The PFC receives substantially less dopaminergic innervation than the striatum, and several studies suggest it may be relatively spared from direct dopaminergic terminal damage even at doses that devastate striatal DA. The early Ricaurte rhesus monkey work found that repeated d-methylamphetamine administration (0.5–16 mg/kg/day) produced a 48% decrease in caudate DA but no significant change in frontal cortex DA (Finnegan, Ricaurte, Seiden & Schuster, 1982). PFC may have different antioxidant enzyme profiles and lower basal DA turnover, potentially conferring relative protection against the autoxidation pathway—though this hasn't been rigorously compared across regions in the same experimental paradigm.

However, PFC is not safe by a different route. This matters a lot for the "cognitive performance" framing of this post. High catecholamine release from stress/stimulant exposure activates α1-AR and D1R signaling cascades in PFC that lead to spine loss and dendritic atrophy through calcium-cAMP-potassium channel mechanisms (Arnsten, 2009). This is a different damage pathway than DA terminal degeneration—it's about prefrontal network architecture degradation, not dopaminergic terminal death. And it's the pathway most directly relevant to the higher-order cognition that makes stimulants attractive for knowledge work in the first place. The irony: the brain region you're trying to enhance is vulnerable through a mechanism the standard neurotoxicity literature barely discusses.

METH is also toxic to serotonergic terminals in multiple brain regions including striatum, hippocampus, and frontal cortex (Ricaurte et al., various), which may be more relevant for MDMA but potentially for high-dose amphetamine exposure as well.

The Primate Dosing Problem

This is where the evidence gets genuinely uncomfortable, and where the field has unresolved contradictions that honest risk reasoning has to sit inside.

The alarming finding. Ricaurte's group treated adult baboons and squirrel monkeys with a 3:1 d/l-amphetamine mixture (mimicking Adderall's formulation) for 4 weeks. Plasma amphetamine concentrations (136 ± 21 ng/mL) matched levels reported in human ADHD patients after 3–6 weeks of treatment (120–140 ng/mL). Both primate species showed 30–50% reductions in striatal dopamine, DOPAC, tyrosine hydroxylase, DAT, and VMAT when sacrificed 2 weeks post-treatment (Ricaurte et al., 2005; reviewed extensively in Berman et al., 2009).

These are not trivial reductions. They're in the same range as effects observed with explicitly neurotoxic dosing regimens in rodents. And the plasma levels matched clinical therapeutic ranges.

A note on Ricaurte's credibility, since it comes up: his earlier MDMA prim

Transient senescent decidual cells act as a niche that educates uterine natural killer (NK) cells to acquire a tolerant phenotype toward the semi‑allogeneic embryo. During the implantation window, FOXO1‑driven senescence triggers a localized IL‑8 rich SASP that not only induces decidual markers but also recruits and activates uterine NK cells. We propose that direct contact or soluble factors from these senescent stromal cells imprint NK cells with a CD56brightCD16- phenotype characterized by heightened angiogenic factor production (VEGF, PLGF) and reduced cytotoxic granule release. This education is time‑limited; successful implantation depends on the timely clearance of senescent cells by uterine NK cells and macrophages, which terminates the educational signal. If clearance is delayed, senescent cells persist, converting the acute educational SASP into a chronic inflammatory milieu that drives NK cell exhaustion and aberrant cytokine secretion, leading to implantation failure or early pregnancy loss. Conversely, premature ablation of senescent cells before NK education is complete yields NK cells lacking the tolerant imprint, resulting in excessive cytotoxic activity toward the trophoblast.

Testable predictions: 1. In vivo depletion of FOXO1+ senescent stromal cells prior to day 4 of decidualization will reduce uterine NK CD56brightCD16- frequency and VEGF secretion, impairing embryo implantation in mice. 2. Adoptive transfer of NK cells cultured with conditioned media from transiently senescent decidual stromal cells will increase NK expression of tolerogenic markers (HLAG, IDO1) and decrease cytotoxicity toward trophoblast spheroids. 3. Persistence of senescent cells beyond the implantation window (e.g., via FOXO1 overexpression) will correlate with increased NK cell expression of exhaustion markers (PD-1, TIM-3) and elevated uterine IL-6/TNF-α, predicting lower litter size. 4. Blocking IL-8 signaling during the senescent phase will disrupt NK cell recruitment and attenuate the tolerogenic NK phenotype, reproducing implantation defects seen in recurrent implantation failure models.

Experiments can use murine models with p16-3MR or FOXO1-CreERT2 reporters to track senescent stromal cells, flow cytometry for NK phenotypes, and implantation assays. Rescue experiments with senolytics administered after NK education will test whether clearing senescent cells post-education improves pregnancy outcomes, distinguishing between detrimental persistence and beneficial transient presence.

Hypothesis

Somatic stem cells can achieve germline‑like durability when subjected to continuous, high‑stringency selection that removes damaged counterparts and simultaneously reprograms local nutrient‑sensing to favor repair over growth.

Mechanistic Rationale

The germline maintains fidelity not by possessing unique repair enzymes but by two linked strategies: (1) ruthless elimination of sub‑optimal cells at each reproductive bottleneck and (2) systemic suppression of IGF‑1 signaling that redirects limiting repair factors to the germ line (2). Somatic tissues lack this double hit; they tolerate a mixed population of healthy and damaged stem cells and experience chronic IGF‑1‑driven anabolic signaling that prioritizes proliferation over maintenance.

We propose that imposing germline‑grade selection on a somatic stem‑cell niche will force the remaining cells to adopt a repair‑centric phenotype. This can be engineered by:

• Inducible apoptosis of damaged stem cells using a CRISPR‑Cas9‑based sensor that activates Caspase‑9 upon detection of persistent DNA double‑strand breaks or mitochondrial membrane depolarization.
• Local knock‑down of IGF‑1 receptor (Igf1r) in the niche via tissue‑specific shRNA, mimicking the systemic IGF‑1 attenuation observed after germline ablation.
• Concurrent over‑expression of TRIM32 to boost proteasome‑mediated clearance of damaged proteins, a mechanism the germline uses to purge interfering maternal factors (3).

Together, these interventions should create a microenvironment where only stem cells with pristine genomes and proteomes survive, and where the surviving cells allocate scarce repair resources to maintenance rather than growth.

Testable Predictions

1. In murine skeletal muscle, satellite‑cell‑specific expression of the DNA‑damage sensor‑Caspase‑9 combo will reduce the fraction of Pax7⁺ cells harboring γH2AX foci by >40 % after irradiation, compared with controls.
2. Niches with Igf1r shRNA will show a 2‑fold increase in autophagic flux (LC3‑II/I ratio) and a 30 % rise in NAD⁺ levels, indicating heightened catabolic repair mode.
3. Adding TRIM32 over‑expression will further lower ubiquitinated protein aggregates by ~50 % and improve grip‑strength recovery post‑injury by 25 % relative to IGF‑1 attenuation alone.
4. Longitudinal cohorts will exhibit delayed onset of age‑related frailty (frailty index increase <0.02 / month) without a measurable decline in litter size, indicating that somatic repair can be uncoupled from reproductive trade‑offs when selection is cell‑autonomous.

Falsifiability

If inducing apoptosis of damaged satellite cells fails to reduce their mutational burden, or if local IGF‑1 attenuation does not increase repair‑marker activity despite TRIM32 over‑expression, the hypothesis that germline‑level selection pressure is sufficient to confer somatic immortality‑like fidelity will be refuted. Conversely, observing the predicted improvements would support the view that the germline’s advantage stems from enforceable selection and resource reallocation, not from an intrinsic, immutable repair superiority.

The aging program of the coral holobiont is governed not by host nuclear or mitochondrial DNA but by the mitochondrial genome of its Symbiodiniaceae symbionts. Subtle variation in symbiont mtDNA alters electron transport chain efficiency, modulating reactive oxygen species (ROS) output that acts as a retrograde signal to the host nucleus. This ROS signal reshapes host gene networks governing apoptosis, autophagy, and immune activation, thereby setting the pace of holobiont senescence and bleaching susceptibility. In essence, symbiont mtDNA functions as a metabolic rheostat that translates environmental stress into host‑level aging outcomes.

Mechanistically, differences in symbiont mtDNA-encoded subunits of cytochrome b and COX1 change the proton‑pumping capacity of the symbiont respiratory chain. Higher ROS production triggers host MAPK and NF‑κB pathways, upregulating caspases and lysosomal enzymes that accelerate cellular turnover. Conversely, low‑ROS haplotypes sustain a more reduced state, promoting host antioxidant gene expression (e.g., superoxide dismutase, glutathione peroxidase) and delaying apoptosis. This creates a feedback loop where host‑derived nitric oxide can further modulate symbiont mitochondrial membrane potential, fine‑tuning ROS emission.

Testable predictions: 1. Isogenic Symbiodiniaceae lines differing only at a single mtDNA heteroplasmic site (e.g., a synonymous mutation in COX1) will produce measurable ROS gradients under identical light and temperature conditions. 2. Exposing aposymbiotic Acropora juveniles to these lines will yield divergent host transcriptomic profiles: high‑ROS lines will elevate expression of caspase‑3, bax, and hsp70, while low‑ROS lines will upregulate sod2, foxO, and lon protease. 3. Chronic thermal stress (32 °C for 7 days) will shorten the holobiont lifespan (measured by survival and fecundity) in high‑ROS symbiont associations by ≥30 % compared with low‑ROS associations, independent of symbiont density. 4. Targeted reduction of symbiont mtDNA mutation load using mitoTALENs to shift heteroplasmy toward low‑ROS haplotypes will rescue host longevity and reduce bleaching incidence under stress.

Falsifiability: If manipulation of symbiont mtDNA heteroplasmy fails to alter host ROS signaling, gene expression, or stress‑induced lifespan, or if host longevity remains tightly coupled to host mtDNA mutation load regardless of symbiont genotype, the hypothesis is refuted. This approach shifts focus from the host genome to the symbiont mitochondrion as a tractable, editable locus for enhancing coral resilience.

Hypothesis\n\nSomatic cells can achieve germline‑like genome stability by importing germline‑derived exosomes that deliver active DNA repair and transposon‑silencing machinery.\n\nMechanistic basis\n- Germline exosomes (GExos) contain high levels of OGG1, MES complex subunits, and piRNA‑associated Argonaute proteins, loaded via an ESCRT‑independent pathway that couples cargo binding to exosome biogenesis.[1][2]\n- Somatic cells express low levels of the exosome surface receptor Syndecan‑1 (SDC1), limiting GExos uptake.[3]\n- Forced SDC1 overexpression in somatic tissues creates a permissive entry route, allowing GExos to fuse with endosomes and release their cargo into the cytosol.\n\nTestable predictions\n1. Isolating exosomes from young Drosophila germline stem cells and incubating them with cultured human fibroblasts will increase nuclear OGG1 activity and reduce 8‑oxoguanine lesions by >30% after 24 h (measured by comet assay).\n2. Transgenic mice with somatic‑specific SDC1 overexpression that receive periodic intravenous injections of purified mouse ovarian GExos will show (a) delayed telomere shortening in liver and muscle, (b) reduced p16^INK4a^‑positive senescent cells, and (c) improved grip strength and maze performance at 24 months versus controls.\n3. Blocking exosome release from germline cells using Rab27a knockdown will abolish the protective effect, confirming that the benefit depends on EV trafficking.\n\nFalsifiability\nThis approach won't need germline manipulation; if somatic SDC1 overexpression combined with germline exosome treatment fails to improve any of the readouts above—specifically, if DNA damage, senescence markers, or functional assays are indistinguishable from untreated aged controls—the hypothesis is falsified. Conversely, a positive result would support the idea that grafting the germline’s ‘cheating’ EV import system onto soma can confer comparable genome maintenance.\n\nBroader implication\nWe can't assume that boosting intrinsic repair pathways is the only way to stay young. Harnessing an existing intercellular transfer system that the germline already uses offers a concrete, exploitable route to extend healthspan without altering the germline itself.\n\nReferences\n[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC4098867/\n[2] https://pmc.ncbi.nlm.nih.gov/articles/PMC10894803/\n[3] https://doi.org/10.1101/2023.11.15.567290\n[4] https://doi.org/10.1101/2024.06.22.600215\n[5] https://doi.org/10.2147/ijn.s170680

Hypothesis

Host cells under combined thermal and acidification stress increase production of reactive oxygen species (ROS) that selectively enrich rare microbiome taxa capable of degrading host-derived antioxidant compounds, thereby modulating the redox environment at the calcifying interface and preserving calcification rates.

Mechanistic basis

• Thermal stress triggers Symbiodiniaceae expulsion and ROS generation (see Oxidative Theory of Coral Bleaching) [https://pmc.ncbi.nlm.nih.gov/articles/PMC12835581/].
• Ocean acidification lowers pH, reducing carbonate ion availability and upregulating host proton pumps, which further elevates intracellular ROS via mitochondrial stress.
• Host ROS act as signaling molecules that upregulate expression of mucin-like glycoproteins and antimicrobial peptides, creating a niche favoring rare bacteria equipped with catalase, peroxidase, or alternative oxidase genes (e.g., rare Rhodobactereae and Microtrichales lineages).
• These rare taxa metabolize host-derived ROS and exude bicarbonate or organic carbon that can be transferred to the calcifying epithelium, locally raising pH and Ωaragonite.
• Consequently, corals with a microbiome enriched in ROS-scavenging rare taxa maintain higher calcification under combined stress, while those lacking this consortium show accelerated skeletal degradation.

Testable predictions

1. Exposing Acropora fragments to elevated temperature (+2°C) and low pH (pH 7.8) will increase host ROS levels measured by DCFDA fluorescence within 48 h.
2. 16S rRNA amplicon sequencing will reveal a significant rise in relative abundance of rare (<0.1% of community) bacterial OTUs possessing antioxidant genes (identified via metagenomic screening) compared to ambient controls.
3. Inhibiting host ROS production with the antioxidant N-acetylcysteine will blunt the enrichment of these rare taxa and reduce calcification rates relative to untreated stressed fragments.
4. Re-inoculating stressed fragments with a cultured consortium of ROS-degrading rare isolates will rescue calcification to near-control levels, whereas inoculating with a control bacterial mix will not.

Potential pitfalls

• Rare taxa may be below detection limits; using spike-in standards and long-read metagenomics can improve sensitivity.
• ROS measurements must be compartment-specific (surface mucus vs. tissue) to avoid confounding signals from symbiont photosynthesis.
• Scaling from fragment experiments to whole colonies requires accounting for flow-dependent nutrient exchange.

If falsified—i.e., no correlation between host ROS, rare taxon enrichment, and calcification preservation—then the hypothesis that host-driven oxidative priming selects for protective rare microbes would be rejected, prompting focus on alternative mechanisms such as direct ion-transport regulation or symbiont-mediated carbon recycling.

Hypothesis

Host mTOR activity acts as a civilization‑versus‑survival dial that determines whether the coral holobiont invests in skeletal growth and symbiont photosynthesis (civilization mode) or shifts to autophagy‑driven stress resistance and mucus remodeling (survival mode). Under combined thermal stress and ocean acidification, sustained mTOR activation inhibits the lysosomal transcription factor TFEB, blocking autophagy and reducing the secretion of mucin‑bound glycans that select for beneficial, ROS‑scavenging bacteria. Consequently, the mucus microbiome loses nitrogen‑cycling and vitamin‑producing taxa, while opportunistic pathogens proliferate, precipitating bleaching and mortality.

Mechanistic Rationale

• mTORC1 phosphorylates and retains TFEB in the cytosol, preventing its nuclear translocation and the transcription of lysosomal and autophagy genes (https://academic.oup.com/jxb/article/73/20/6993/6609545).
• In cnidarians, host mTOR integrates photosynthate from Symbiodiniaceae to drive calcification and anabolic metabolism (http://nbn-resolving.de/urn:nbn:de:bsz:352-2-168yqys8a9b3e7).
• When mTOR remains active despite nutrient limitation or stress, the host continues to prioritize growth, depleting intracellular amino acid pools that would otherwise trigger AMPK‑ULK1‑mediated autophagy initiation.
• Reduced autophagy diminishes autophagosome‑mediated secretion of mucin precursors and associated oligosaccharides, altering the chemical landscape of the coral surface mucus layer (https://researchportal.scu.edu.au/esploro/outputs/journalArticle/Rewiring-coral-Anthropogenic-nutrients-shift-diverse/991013138313702368).
• Beneficial microbes that rely on host‑derived glycans for nitrogen acquisition and vitamin synthesis (e.g., Halomonadaceae, Rhodobacteraceae) lose their niche, while opportunistic vibrios that thrive on protein‑rich mucus dominate (https://academic.oup.com/femsre/article/47/2/fuad005/7071893).
• The resulting dysbiotic mucus layer fails to scavenge ROS, amplifying oxidative damage to symbiont photosystems and accelerating bleaching.

Testable Predictions

1. Pharmacological inhibition of mTOR with rapamycin under heat‑acid stress will increase nuclear TFEB, elevate LC3‑II/autophagosome markers, and restore mucin‑glycan secretion compared with DMSO controls.
2. Genetic activation of host mTOR (e.g., constitutively active Rheb) will suppress TFEB nuclear localization, lower autophagy flux, and shift mucus metaproteome toward higher protein‑to‑carbohydrate ratios.
3. Microbiome sequencing of mucus from rapamycin‑treated corals will show enrichment of nitrogen‑fixing and vitamin‑B12 producing taxa, whereas mTOR‑hyperactive corals will exhibit increased relative abundance of Vibrio spp. and reduced diversity.
4. Bleaching outcomes (Fv/Fm decline, symbiont density loss) will be significantly attenuated in rapamycin‑treated fragments and exacerbated in mTOR‑hyperactive fragments after 7‑day exposure to 32 °C and pH 7.8.
5. Exogenous addition of purified host‑derived mucin glycans to mTOR‑hyperactive mucus will partially rescue the beneficial microbiome and ROS‑scavenging capacity, confirming that the glycan shift is a downstream effector of mTOR signaling.

Falsifiability

If rapamycin fails to increase TFEB nuclear localization or autophagy markers under stress, or if microbiome composition and bleaching severity do not diverge between mTOR‑modulated and control groups, the hypothesis that mTOR‑driven autophagy governs mucus‑mediated holobiont resilience would be refuted. Conversely, consistent support across these predictions would substantiate the civilization‑versus‑survival dial as a central control point for coral climate tolerance.